

From: [REDACTED]

Sent: Fri Oct 10 2003 12:48:19 EDT

[REDACTED]
[REDACTED]
[REDACTED];cara.lansden/cambridge/biogen@biogen;carmen.bozic/cambridge/biogen@biogen

To: [REDACTED]

[REDACTED]

Subject: FumaPharm Update

Hi Everyone,

As you know, we have brought a new product in to our pipeline. The product, BG00012, will be developed in Psoriasis and MS. FumaPharm will participate on a Management Team with routine review and buy-in of plans, but the studies will be conducted entirely by Biogen. Rather than wait until the next milestone meeting, I am sending this e-mail to give you a very draft overview of the program because we will need resources assigned immediately.

[REDACTED]

[REDACTED]

[REDACTED]

Currently, [REDACTED] is the Acting Medical Director for Psoriasis, Gilmore O'Neill is the Medical Director for MS, [REDACTED] is the Business Analyst for Psoriasis, [REDACTED] is the Business Analyst for MS, [REDACTED] the MCD for both MS and Psoriasis.

Please contact me if you have any questions or concerns.

[REDACTED]

[REDACTED]